Testosterone Science

Cancer

Testosterone Treatment Improved Sexual and Physical Function for Men After Prostate Cancer Surgery

Specific Claim Evaluated

In a randomized trial of 136 men with testosterone deficiency and undetectable PSA after radical prostatectomy, 12 weeks of testosterone improved sexual activity, desire and physical function compared with placebo, erectile function did not change and no participant had biochemical recurrence.

Primary Research Supporting or Contradicting the Claim

The SPIRIT trial randomized 136 men with low-grade prostate cancer and undetectable PSA for at least 2 years to weekly testosterone cypionate or placebo for 12 weeks; sexual activity improved and no biochemical recurrence occurred, but the trial was not long or large enough to assess clinical recurrence (Bhasin et al., 2026).

Corrected Evidence-Based Interpretation

The release is correct. Findings apply only to men with low-grade disease after prostatectomy and do not establish long-term oncologic safety.

Rationale for Grade

The release reports the null erectile function result and calls for larger, longer studies. Its description of the trial matches the published report.

References

  1. Bhasin S, Burnett AL, Gagliano-Jucá T, Storer TW, Reid KF, Shang YV, Privat F, Chandra MS, Weiss M, Memish-Beleva Y, Lam H, Kibel AS, Pencina KM. Testosterone treatment in prostate cancer survivors with hypogonadism: a randomized clinical trial. JAMA Intern Med. 2026;186(7):805-814. PMID
    Supporting excerpt: "The trial was neither long enough nor large enough to evaluate clinical recurrence"

Post a Comment

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.